Immuno-Oncology
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Allogeneic stem cell transplantation (alloSCT) remains a valuable treatment option for fit patients with acute myeloid leukemia (AML), and the…
Date: 5th April 2023
Insights into the changing role of chemotherapy in lymphoma
Although several novel agents have been implemented in the treatment of Hodgkin and non-Hodgkin lymphoma (HL; NHL), chemotherapy remains the…
Date: 31st March 2023
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
CAR-T cell therapy represents a major breakthrough in the treatment of hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and…
Date: 16th March 2023
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies,…
Date: 10th March 2023
The current status of CAR-T therapy in CLL and challenges in this space
In recent years, novel immunotherapies, including CAR-T cell therapy, have greatly improved treatment options for patients with hematological malignancies. Although CAR-T…
Date: 3rd March 2023
Managing and treating GvHD and other post-transplant complications
Graft-versus-host disease (GvHD) is a common complication associated with allogeneic stem cell transplantation (alloSCT), and can occur in acute and…
Date: 23rd February 2023
Novel immune therapies in MDS and challenges in this space
Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are…
Date: 7th February 2023
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 2nd February 2023
MPN highlights at ASH 2022: novel agents, combinations & the role of immunotherapy
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 26th January 2023
T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 20th January 2023
The importance of CD47 in MDS and other targets of interest
CD47 is a cell surface protein which is overexpressed in several cancer cells and appears to play an important role…
Date: 17th January 2023
CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 9th January 2023